NuCana (NCNA) Deferred Taxes (2017 - 2025)
NuCana (NCNA) reported Deferred Taxes of -$188883.6 for Q4 2025, down 7.42% on a YoY basis from -$204017.7 in Q4 2024, and up 59.43% sequentially from -$465529.9 in Q3 2025.
NuCana (NCNA) Deferred Taxes (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Deferred Taxes data on file, last reported at -$188883.6 in Q4 2025.
- For the quarter ending Q4 2025, Deferred Taxes fell 7.42% year-over-year to -$188883.6; the trailing twelve-month figure through Dec 2025 stood at -$1.8 million (up 59.26% YoY), and the FY2025 full-year result was -$1.5 million, up 65.12% from the prior year.
- Deferred Taxes advanced to -$188883.6 in Q4 2025, from -$465529.9 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of -$175839.8 in Q4 2024 to a low of -$2.8 million in Q4 2021.
- A 5-year average of -$1.5 million and a median of -$1.6 million in 2023 frame the typical range for Deferred Taxes.
- Peak annual rise in Deferred Taxes reached 89.23% in 2024, while the deepest fall reached 87.3% in 2024.
- Tracing NCNA's Deferred Taxes over 5 years: stood at -$2.8 million in 2021, then soared by 46.19% to -$1.5 million in 2022, then fell by 8.64% to -$1.6 million in 2023, then jumped by 89.23% to -$175839.8 in 2024, then fell by 7.42% to -$188883.6 in 2025.
- Business Quant data shows NCNA's Deferred Taxes at -$188883.6 in Q4 2025, -$465529.9 in Q3 2025, and -$175839.8 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -188,883.60 |
| Sep 30, 2025 | -465,529.94 |
| Dec 31, 2024 | -175,839.75 |
| Sep 30, 2024 | -961,482.12 |
| Jun 30, 2024 | -1.61 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -1.63 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -857,183.76 |
| Mar 31, 2023 | -1.21 Mn |
| Jun 30, 2022 | -1.50 Mn |
| Mar 31, 2022 | -2.73 Mn |
| Dec 31, 2021 | -2.79 Mn |
| Sep 30, 2021 | -2.63 Mn |
| Jun 30, 2021 | -2.22 Mn |
| Mar 31, 2021 | -2.35 Mn |
| Dec 31, 2020 | -2.24 Mn |
| Sep 30, 2020 | -1.55 Mn |
| Jun 30, 2020 | -1.59 Mn |
| Mar 31, 2020 | -1.68 Mn |